Conclusion GLP-1 agonists are a valuable addition to biologics in managing both inflammation and metabolic health in chronic autoimmune conditions
"The question is, what other animal has something to teach us that can be of future value
Acknowledgements The authors would like to thank Thomas Rohban, MD, and Magalie El Hajj, PharmD, from Partner 4 Health (Paris, France) for providing medical writing support in accordance with Good Publication Practice (GPP3) guidelines
First of all, at 5-foot-1, my 30-ish extra pounds rendered me technically overweight by body mass index
All participants were overweight or obese and were on injectable semaglutide or tirzepatide for either obesity or T2DM
48% discontinuation among weight loss GLP-1 users 33% discontinuation among diabetes GLP-1 users Discontinuation of GLP-1 therapy is associated with metabolic rebound, including weight regain, rising blood pressure, and worsening glycemic control, undermining both clinical outcomes and the value of initial investment
